Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Weizmannia Coagulans BC179 Alleviates Post-Alcohol Discomfort May Via Taurine-Related Metabolism and Antioxidant Regulation: A Randomized, Double-Blind，Placebo-Controlled Trial

NCT06899620 is registered in ClinicalTrials.gov with Wecare Probiotics Co., Ltd. as lead sponsor.

NCT NCT06899620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06899620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Weizmannia Coagulans BC179 Alleviates Post-Alcohol Discomfort May Via Taurine-Related Metabolism and Antioxidant Regulation: A Randomized, Double-Blind，Placebo-Controlled Trial
Lead sponsor
Wecare Probiotics Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
July 1, 2024
Completion date
July 20, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drinking behavior